PPARγ agonist rosiglitazone enhances glucose uptake into podocytes by enhancing GLUT1 translocation to the plasma membrane (75), and remarkably, GLUT1 overexpression in podocytes protects against DKD (72). Here, SLC2A1 is linked to diabetic kidney disease.